# Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors

> **NCT05388487** · PHASE1 · UNKNOWN · sponsor: **HighField Biopharmaceuticals Corporation** · enrollment: 54 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** HF1K16 /Arm 45 mg/m²
- **DRUG:** HF1K16 /Arm 90 mg/m²
- **DRUG:** HF1K16 /Arm 120 mg/m²
- **DRUG:** HF1K16 /Arm 160 mg/m²
- **DRUG:** HF1K16 /Arm 120 mg or 180 mg

## Key facts

- **NCT ID:** NCT05388487
- **Lead sponsor:** HighField Biopharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-16
- **Primary completion:** 2025-04
- **Final completion:** 2025-11
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05388487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05388487, "Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05388487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*